

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



利君國際醫藥(控股)有限公司

Lijun International Pharmaceutical (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

RESIGNATION OF DIRECTOR AND CHANGE OF AUTHORIZED REPRESENTATIVE

The board of directors (the “**Board**”) of Lijun International Pharmaceutical (Holding) Co., Ltd. (the “**Company**”) announces that Ms. Sun Xinglai (“**Ms. Sun**”) has resigned as an executive Director and Authorized Representative of the Company with effect from 29 July 2011. Ms. Sun, aged 55, wishes to be retired from her post in order to focusing on her other personal pursuits. The Board also announces that Mr. Bao Leyuan, an executive Director of the Company has been appointed as Authorized Representative of the Company with effect from 29 July 2011.

Ms. Sun has confirmed that she has no disagreement with the Board and there are no matters that need to be brought to the attention of The Stock Exchange of Hong Kong Limited or/and the shareholders of the Company in relation to her resignation.

The Board would like to take this opportunity to express its appreciation to Ms. Sun for her valuable contribution to the Company during her tenure of office as an executive Director and Authorised Representative of the Company.

By order of the Board
Sze Wing Kin, Pierre
Company Secretary

Hong Kong, 29 July 2011

As at the date of this announcement, the Board comprises Mr. Wu Qin, Mr. Qu Jiguang, Mr. Xie Yunfeng, Mr. Huang Chao, Mr. Wang Xianjun, Mr. Duan Wei, Ms. Zhang Guifu, Mr. Bao Leyuan and Ms. Gao Shuping as executive Directors, Mr. Liu Zhiyong as non-executive Director, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.